Literature DB >> 19318085

Elevated cleavage of human immunoglobulin gamma molecules containing a lambda light chain mediated by iron and histidine.

David Ouellette1, Leslie Alessandri, Reema Piparia, Aima Aikhoje, Adam Chin, Czeslaw Radziejewski, Ivan Correia.   

Abstract

Monoclonal antibodies in liquid formulation undergo nonenzymatic hydrolysis when stored at 5 degrees C for extended periods. This hydrolysis is enhanced at extreme pH and high temperature. In this study we discover that iron in the presence of histidine also enhanced cleavage of human immunoglobulin gamma (IgG) molecules containing a lambda light chain when incubated at 40 degrees C. The level of cleavage was concentration dependent on both iron and histidine levels. Enhanced cleavage with iron and histidine was not observed on IgG molecules containing a kappa light chain. Using CE-SDS to quantify levels of Fab+Fc, the Fab arm, and free light chain (LC) and heavy chain (HC) fragments, we show that cleavage resulted in elevated levels of free light and heavy chain fragments. Using MS we find elevated scission between residues E/C on the LC resulting in LC fragment 1-215. We also observed enhanced cleavage between S/C residues of the HC resulting in HC fragment 1-217. The corresponding Fab+Fc fragment beginning with cys-218 was not found. Instead, we find elevation of a Fab+Fc fragment that began with aspartic acid (cleavage between C/D). Further studies to understand how iron and histidine enhance cleavage of lambda light chain IgG molecules are ongoing.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19318085     DOI: 10.1016/j.ab.2009.03.027

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  12 in total

Review 1.  Fragmentation of monoclonal antibodies.

Authors:  Josef Vlasak; Roxana Ionescu
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

Review 2.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

3.  6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.

Authors:  Alain Beck; Thierry Wurch; Janice M Reichert
Journal:  MAbs       Date:  2011-03-01       Impact factor: 5.857

Review 4.  Forced degradation of recombinant monoclonal antibodies: A practical guide.

Authors:  Christine Nowak; Jason K Cheung; Shara M Dellatore; Amit Katiyar; Ram Bhat; Joanne Sun; Gomathinayagam Ponniah; Alyssa Neill; Bruce Mason; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2017-08-30       Impact factor: 5.857

5.  Breaking the light and heavy chain linkage of human immunoglobulin G1 (IgG1) by radical reactions.

Authors:  Boxu Yan; Daniel Boyd
Journal:  J Biol Chem       Date:  2011-05-23       Impact factor: 5.157

6.  Metal ion interactions with mAbs: Part 1.

Authors:  Zephania Kwong Glover; Louisette Basa; Benjamin Moore; Jennifer S Laurence; Alavattam Sreedhara
Journal:  MAbs       Date:  2015       Impact factor: 5.857

7.  Metal Ion Interactions with mAbs: Part 2. Zinc-Mediated Aggregation of IgG1 Monoclonal Antibodies.

Authors:  Shrenik Mehta; Heather Flores; Benjamin Walters; Alavattam Sreedhara
Journal:  Pharm Res       Date:  2021-08-11       Impact factor: 4.200

Review 8.  Main Quality Attributes of Monoclonal Antibodies and Effect of Cell Culture Components

Authors:  Fatemeh Torkashvand; Behrouz Vaziri
Journal:  Iran Biomed J       Date:  2017-04-20

9.  Identification of N-Terminally Truncated Derivatives of Insulin Analogs Formed in Pharmaceutical Formulations.

Authors:  Joanna Zielińska; Jacek Stadnik; Anna Bierczyńska-Krzysik; Dorota Stadnik
Journal:  Pharm Res       Date:  2018-05-16       Impact factor: 4.200

Review 10.  Photo-Oxidation of Therapeutic Protein Formulations: From Radical Formation to Analytical Techniques.

Authors:  Elena Hipper; Michaela Blech; Dariush Hinderberger; Patrick Garidel; Wolfgang Kaiser
Journal:  Pharmaceutics       Date:  2021-12-28       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.